0001564590-20-012056.txt : 20200320 0001564590-20-012056.hdr.sgml : 20200320 20200320170119 ACCESSION NUMBER: 0001564590-20-012056 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20200320 FILED AS OF DATE: 20200320 DATE AS OF CHANGE: 20200320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liminal BioSciences Inc. CENTRAL INDEX KEY: 0001351172 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39131 FILM NUMBER: 20732719 BUSINESS ADDRESS: STREET 1: 440 BOULEVARD ARMAND STREET 2: FRAPPIER #300 CITY: LAVAL STATE: A8 ZIP: H7V 4B4 BUSINESS PHONE: 514-341-2115 MAIL ADDRESS: STREET 1: 440 BOULEVARD ARMAND STREET 2: FRAPPIER #300 CITY: LAVAL STATE: A8 ZIP: H7V 4B4 FORMER COMPANY: FORMER CONFORMED NAME: ProMetic Life Sciences Inc DATE OF NAME CHANGE: 20060126 6-K 1 lmnl-6k_20200320.htm 6-K lmnl-6k_20200320.htm

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of March 2020

 

Commission File Number: 001-39131

 

LIMINAL BIOSCIENCES INC.

(Translation of registrant’s name into English)

 

 

440 Armand-Frappier Boulevard, Suite 300

Laval, Québec

H7V 4B4

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  

☒ Form 20-F   ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 


EXHIBIT LIST

 

Exhibit

 

Description

 99.1

 

Press release dated March 20, 2020.

 

 


 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liminal BioSciences Inc.

 

 

 

 

Date: March 20, 2020

 

 

 

By:

 

/s/ Kenneth Galbraith

 

 

 

 

 

 

Name

 

Kenneth Galbraith

 

 

 

 

 

 

Title:

 

Chief Executive Officer

 

 

 

 

 

 

 EX-99.1 2 lmnl-ex991_6.htm EX-99.1 lmnl-ex991_6.htm

 

Exhibit 99.1

 

Press Release

For immediate release

 

LIMINAL BIOSCIENCES REPORTS FOURTH QUARTER AND 2019 YEAR END RESULTS

 

Key 2019 Events:

 

•

$114.4 million aggregate gross proceeds were raised through a combination of a private placement offering of our common shares, followed by an equity rights offering

•

Listing of common shares on the Nasdaq Global Market (“Nasdaq”) completed in the fourth quarter

•

Divestiture of Prometic Bioseparations Limited (“PBL”), our affinity chromatography resins business, to a subsidiary of KKR & Co. in the fourth quarter for potential gross proceeds of up to $78.5 million

•

Strengthening of the Board of Directors and leadership team, including the addition of Ms. Moira Daniels as Head of Regulatory Affairs and Quality Assurance also in the fourth quarter

 

LAVAL, QC, and CAMBRIDGE, UK – March 20, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, today reported its financial results for the fourth quarter and year-ended December 31, 2019.

 

“Since becoming CEO in April 2019, we have made significant progress on the strategic transformation of our Company”, said Kenneth Galbraith, Liminal BioSciences’ Chief Executive Officer.  “We have taken substantial steps, including the divestment of our

1

Press Release for immediate release

 

 

 

bioseparations business, to allow us to simplify our operations and continue the transition of Liminal BioSciences from a multi-platform company into a streamlined organization focusing, in the future, on the development and commercialization of small molecule product candidates with a growing diversity of biological targets and product candidate development programs.”

 

“We have taken steps to improve our financial position through additional capital raised in equity offerings in the second quarter, and by managing our cash runway. We expect to close our Rockville, Maryland operations by the end of 2020.”

 

“We continue to review all of our product candidate development programs in order to streamline our R&D strategy. We believe this will allow us to focus on advancing the development of our most promising clinical-stage product candidates, while remaining committed to the development of our early-stage R&D pipeline of potential new product candidates.”

 

“We are looking forward to our expected resubmission, in the first half of 2020, of a Biological License Application (“BLA”) with the United States Food and Drug Administration (“FDA”) for Ryplazim® (plasminogen) for the treatment of patients with congenital plasminogen deficiency, and working with the FDA to review our anticipated resubmission during 2020,” continued Mr. Galbraith. “Our first product approval from the FDA, if received, would be a historic event for Liminal BioSciences and our shareholders who have supported the Company’s efforts to make this potential treatment available to patients in the United States, and eventually other countries.”

 

Anticipated 2020 Milestones

 

•

Anticipated resubmission of a BLA with FDA for Ryplazim® for the treatment of congenital plasminogen deficiency, in the first half of 2020

•

Exploring alternatives for the future commercialization of Ryplazim®, if approved, including through a third-party marketing collaboration, and other ongoing preparation for the potential commercial launch of Ryplazim®, if approved, in the United States

•

Continued clinical development of fezagepras and PBI-4547

2

Press Release for immediate release

 

 

 

•

Anticipated development of oral GPR84 antagonists for the treatment of fibrosis

 

Fourth Quarter and Year End 2019 Financial Results:

Following the sale of PBL, we have restated the prior periods to remove the impact of those operations from the all lines in the financial statements and have reclassified those results to the discontinued operations line in the financial statement:

 

 

•

Working Capital: As of December 31, 2019, the Company’s working capital, i.e. the current assets net of current liabilities, amounts to a surplus of $63.6 million compared to $5.1 million as of December 31, 2018. Our cash and cash equivalents position at December 31, 2019 was $61.3 million. We also have an unutilized line of credit from Structured Alpha LP, or SALP, in the amount of $29.1 million as of March 20, 2020.

 

•

Revenues were $1.1 million for the fourth quarter of 2019, as compared to $3.4 million for the fourth quarter of 2018. The decrease was principally due to sales of excess normal source plasma inventory that occurred in 2018 and were not repeated in the fourth quarter of 2019.

 

•

R&D expenses were $17.3 million for the fourth quarter of 2019, as compared to $19.2 million for the fourth quarter of 2018. This was primarily due to a decrease in inventory expensed to supply clinical trial patients and third-party costs incurred for the clinical trials, and due to lower rental costs included in R&D due to the impact of adoption of IFRS 16, Leases. This was partially offset by an increase in compensation expense including severances due to headcount reductions.

 

•

Administration, selling and marketing (“SG&A”) expenses were $10.3 million for the fourth quarter of 2019, as compared to $10.2 million for the fourth quarter of 2018. The increase was primarily due to the increase in the director and officer insurance following the listing of our common shares on the Nasdaq, which was mostly offset by a reduction in employee compensation expense.

 

•

Net loss from continuing operations was $39.6 million for the fourth quarter of 2019 compared to $142.1 million for the fourth quarter of 2018. The decrease was mainly driven by a decrease of impairment losses of $137.6 million, the reduction in finance costs due to the debt restructuring in April 2019 and the absence of a gain on extinguishment of liabilities of $34.9 million due to the debt modification that took place during the quarter ended December 31, 2018.

3

Press Release for immediate release

 

 

 

 

•

Net loss and net loss attributable to the Company’s shareholders were $14.5 million and $14.4 million, respectively, for the fourth quarter of 2019 compared to a net loss and a net loss attributable to the Company’s shareholders of $141.3 million and $103.0 million, respectively, for the fourth quarter of 2018. Net loss attributable to the Company’s shareholders on a basic and diluted per share basis was $0.62 for the fourth quarter of 2019 compared to $124.04 per share for the fourth quarter of 2018.

 

•

Revenues were $4.9 million for the year ended December 31, 2019, as compared to $24.6 million for the year ended December 31, 2018. The decrease was mainly due to the sales of excess normal source plasma inventory in 2018.

 

•

R&D expenses were $75.1 million for the year ended December 31, 2019, as compared to $84.9 million for the year ended December 31, 2018. The decrease was primarily due to a reduction in spending with third parties on clinical trials, preclinical studies and the validation of analytical assays and in-process controls in the manufacturing of Ryplazim®.

 

•

SG&A expenses were $45.3 million for the year ended December 31, 2019, as compared to $29.4 million for the year ended December 31, 2018. The increase was mainly attributable to employee compensation expense, which includes an increase in share-based payments expense of $10.7 million, as well as legal and audit fees of $2.7 million. This was partially offset by a decrease in consultant fees relating to the potential marketing of products.

 

•

Net loss from continuing operations was $234.2 million for the year ended December 31, 2019, as compared to $239.8 million for the year ended December 31, 2018. The decrease was mainly driven by the decrease on the impairment losses of $137.6 million in year ended December 31, 2019 compared to the corresponding period in 2018. This was partially offset by an increase of the loss on extinguishment of liabilities of $126.0 million which was principally caused by the debt restructuring that occurred in April 2019. The increase in the share-based payments expense of $15.1 million was partially offset by the decrease in other R&D expenses.

 

•

Net loss and net loss attributable to the Company’s shareholders were $206.8 million and $205.7 million, respectively, for the year ended December 31, 2019 compared to a net loss and a net loss attributable to the Company’s shareholders of $237.9 million and $195.4 million, respectively, for the year ended December 31, 2018. Net loss attributable to the Company’s shareholders on a

4

Press Release for immediate release

 

 

 

 

basic and diluted per share basis was $12.81 for the year ended December 31, 2019 compared to $235.95 per share for the year ended December 31, 2018.

 

 

About Liminal BioSciences Inc.

Liminal BioSciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need. Liminal BioSciences has a deep understanding of certain biological targets and pathways that have been implicated in the fibrotic process, including fatty acid receptors such as G-protein-coupled receptor 40, or GPR40, and G-protein-coupled receptor 84, or GPR84, and peroxisome proliferator-activated receptors, or PPARs. In preclinical studies, we observed that targeting these receptors promoted normal tissue regeneration and scar resolution, including preventing the progression of, and reversing established fibrosis. We also have encouraging clinical data that we believe supports the translatability of our preclinical data observations to the clinic.  We have leveraged this understanding, as well as our experience with generating small molecules, to build a pipeline of differentiated product candidates. Our lead small molecule product candidate, fezagepras (PBI-4050), is expected to enter an additional Phase 1 clinical trial to evaluate multiple ascending doses of fezagepras in healthy volunteers, at dose levels higher than those previously evaluated in our completed Phase 1 and Phase 2 clinical trials. The data from this Phase 1 clinical trial will inform dose selection for future clinical trials of fezagepras, including placebo-controlled, randomized Phase 2 clinical trials in respiratory disease indications such as Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILDs).

 

Liminal BioSciences has also leveraged its experience in bioseparation technologies through its wholly-owned subsidiary Prometic Bioproduction Inc. to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived product candidate is Ryplazim® (plasminogen), for which the Company expects to resubmit a BLA with the FDA in the first half of 2020 seeking approval to treat patients with congenital plasminogen deficiency.

 

5

Press Release for immediate release

 

 

 

Liminal BioSciences has active business operations in Canada, the United Kingdom and the United States.

 

Forward Looking Statement

This press release contains forward-looking statements about Liminal BioSciences’ objectives, strategies and businesses and unaudited financial information that involve risks and uncertainties. Forward‐looking information includes statements concerning, among other things, statements with respect to the timing of any planned BLA resubmission, development of R&D programs, the timing of initiation of clinical trials, the exploration of alternatives for the future commercialization of Ryplazim®, if approved, including through a third-party marketing collaboration, and the potential commercial launch of Ryplazim®, if approved.

 

These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. At this stage, the product candidates of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, Liminal BioSciences’ ability to develop, manufacture, and successfully commercialize product candidates, if ever, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical trials, the ability of Liminal BioSciences’ to take advantage of business opportunities in the pharmaceutical industry, uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the filings the Company makes with the U.S. Securities and Exchange Commission from time to time. As a result, we cannot guarantee that any forward-looking statement will materialize. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof.

 

6

Press Release for immediate release

 

 

 

We assume no obligation to update any forward-looking statement contained in this Press Release even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

 

For further information please contact:                           

Bruce Pritchard

b.pritchard@liminalbiosciences.com

+1 450.781.0115

 

Patrick Sartore

p.sartore@liminalbiosciences.com

+1 450.781.0115

 

7

Press Release for immediate release

 

 

 GRAPHIC 3 g3t23f1wdtlc000001.jpg GRAPHIC begin 644 g3t23f1wdtlc000001.jpg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�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end